InflaRx (IFRX) shares sank 60% after the company said Wednesday it plans to discontinue development of vilobelimab in pyoderma gangrenosum, a rare and inflammatory skin disease.
More than 5.48 million shares traded intraday, compared with a daily average of about 301,000.
Cemtrex (CETX) said it priced a firm commitment underwritten public offering of 1.25 million shares at $1.00 apiece.
Shares slumped 46%, with intraday trading volume of over 2.56 million against a daily average of about 299,000.
Exodus Movement (EXOD) filed a registration statement late Tuesday for the sale of up to $1 billion of securities, including class A stock and debt, from time to time.
Shares dropped 21% as intraday trading volume rose to more than 220,000 from a daily average of roughly 96,000.
Price: 0.73, Change: -1.09, Percent Change: -59.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.